Global Thyroid Eye Disease Treatment Market – Dynamics
Key players are strengthening their market position through strategic mergers, agreements, and acquisitions which is expected to propel growth of the thyroid eye disease treatment market over the forecast period. For instance, in May 2017, Horizon Therapeutics plc acquired the River Vision Development Corp. and its pipeline drug teprotumumab, a human monoclonal antibody for the treatment of thyroid eye disease. This acquisition is expected to cater to unmet medical needs for the treatment of rare diseases such as thyroid eye disease.
Moreover, increasing launches and approvals of new drugs for treating thyroid eye disease is expected to drive growth of the thyroid eye disease treatment market. For instance, in January 2020, Horizon Therapeutics plc, received approval from the U.S. Food and Drug Administration (FDA) for Tepezza, indicated for the treatment of thyroid eye disease.
Thyroid Eye Disease Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients